Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
USRE44638E1 · kind E1 · reissue
34Cited by
45References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2012 |
| Grant date | Dec 10, 2013 |
| Priority date | — |
| Expiry date | Dec 28, 2032 |
Classification
- Technology area (CPC —)General
Abstract
The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3Kδ activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.